Cancer is a major health issue worldwide, and the global burden of cancer is expected to
increase in the coming years. Whereas the limited success with current therapies has driven …

Identified as a hallmark of cancer, metabolic reprogramming allows cancer cells to rapidly
proliferate, resist chemotherapies, invade, metastasize, and survive a nutrient-deprived …

A circuit level understanding of immune cells and hematological cancers has been severely
impeded by a lack of techniques that enable intracellular perturbation without significantly …

Over the past two decades, the field of multiple sclerosis (MS) has been transformed by the
rapidly expanding arsenal of new disease modifying therapies (DMTs). Current DMTs for MS …

The tumour microenvironment and genetic alterations collectively influence drug efficacy in
cancer, but current evidence is limited and systematic analyses are lacking. Using chronic …

EBV infection causes mononucleosis and is associated with specific subsets of B cell
lymphomas. Immunosuppressed patients such as organ transplant recipients are particularly …

Leflunomide, an inhibitor of dihydroorotase dehydrogenase and thereby pyrimidine
synthesis, was approved for treatment of rheumatoid arthritis in 1998. During the following …

We pursued a structure-guided approach toward the development of improved
dihydroorotate dehydrogenase (DHODH) inhibitors with the goal of forming new interactions …

A fascinating question of modern biology is how a limited number of signaling pathways
generate biological diversity and crosstalk phenomena in vivo. Well-defined …

Simple Summary Ovarian cancer remains the deadliest cancer of the female reproductive
system. There is a significant body of evidence that has demonstrated that Signal …